ישראל - עברית - Ministry of Health

halperin n.h. medic ltd, israel - clindamycin as phosphate - פתילות - clindamycin as phosphate 100 mg/unit - clindamycin

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - fluphenazine decanoate - תמיסה להזרקה - fluphenazine decanoate 25 mg/ml - fluphenazine - fluphenazine - management of psychotic disorders.

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - haloperidol as decanoate - תמיסה להזרקה - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - long term maintenance treatment of schizophrenia and mental or behaivoral problems.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 267 mg - pirfenidone

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 801 mg - pirfenidone

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - dutasteride - קפסולות רכות - dutasteride 0.5 mg - dutasteride

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin